Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies at Delivery in Women, Partners, and Newborns

Egerup, Pia; Olsen, Line; Christiansen, Ann-Marie Hellerung; Westergaard, David; Severinsen, Elin Rosenbek; Hviid, Kathrine Vauvert Römmelmayer; Kolte, Astrid Marie; Boje, Amalie Dyhrberg; Bertelsen, Marie-Louise Mathilde Friis; Prætorius, Lisbeth; Zedeler, Anne; Nielsen, Josefine Reinhardt; Bang, Didi; Berntsen, Sine; Ethelberg-Findsen, Jeppe; Storm, Ditte Marie; Bello-Rodríguez, Judith; Ingham, Andreas; Ollé-López, Joaquim; Hoffmann, Eva R.; Wilken‐Jensen, Charlotte; Krebs, Lone; Jørgensen, Finn Stener; Westh, Henrik; Jørgensen, Henrik L.; Freiesleben, Nina la Cour; Nielsen, Henriette Svarre

doi:10.1097/aog.0000000000004199

Cited by 50 publications

(56 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Perinatal results are reassuring, and no neonatal complications were associated with maternal SARS-COV-2 infection in previous studies [ 15 , 16 ]. Egerup et al [ 25 ] also found no differences between patients with positive versus negative antibodies in neonatal complications. We found no significant differences in APOs among our three groups, and none of the neonatal infections were by SARS-CoV-2.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Screening of severe acute respiratory syndrome coronavirus-2 infection during labor and delivery using polymerase chain reaction and immunoglobulin testing

Savirón-Cornudella¹,

Villalba²,

Esteban

et al. 2021

Life Sciences

View full text Add to dashboard Cite

Aims To assess severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection during labor and delivery with polymerase chain reaction (PCR) and using immunoglobulin G and M testing to correlate with maternal and perinatal outcomes. Main methods Pregnant women admitted for labor and delivery at two Spanish hospitals were screened for SARS-CoV-2 infection by PCR test and by detection of serum immunoglobulins G and M. Maternal and perinatal outcomes were compared in women with laboratory evidence of SARS-CoV-2 infection with those with negative tests. Key findings Between March 31st and September 30th, 2020, 1211 pregnant women were screened for SARS-CoV-2 infection. The prevalence of laboratory evidence of SARS-CoV-2 infections was 5.4% ( n = 65), corresponding to (i) 22 ongoing infections at admission, including two with mild clinical symptoms and 20 asymptomatic women; (ii) 43 cases of previous SARS-CoV-2 exposure; (iii) and 1146 women who were negative for both SARS-CoV-2 PCR and serological test. None of the screened mothers required hospital admission for coronavirus disease before or after delivery, nor were any of the newborns admitted to the intensive care unit. All newborns from mothers with positive PCR on admission were PCR negative. There were no significant differences in maternal or perinatal outcomes among the three studied groups. Significance Ongoing or previous SARS-CoV-2 infection with asymptomatic or mild clinical symptoms detected during screening in pregnant women at labor and delivery do not have a higher rate of adverse maternal or perinatal outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Egerup et al [ 25 ] studied a population of 1313 pregnant women, in Copenhagen (Denmark), from April to July 2020, including 28 cases of positive antibodies and one case of positive PCR. The study concluded that SARS-CoV-2 infection was not associated with obstetric complications in pregnant women who had had the disease.…”

Section: Discussionmentioning

confidence: 99%

Screening of severe acute respiratory syndrome coronavirus-2 infection during labor and delivery using polymerase chain reaction and immunoglobulin testing

Savirón-Cornudella¹,

Villalba²,

Esteban

et al. 2021

Life Sciences

View full text Add to dashboard Cite

show abstract

“…One other study, in which SARS-CoV-2 infection during pregnancy was evaluated using antibody testing in a Danish sample, did not find a difference in CD rate between antibody positive and negative women. However, the absolute number of seropositive women in that study was low (n=28) 41 . Our findings may be influenced by the small sample size, variation in clinical practice, or unmeasured confounding factors.…”

Section: Resultsmentioning

confidence: 73%

Seroprevalence of SARS-CoV-2 during pregnancy and associated outcomes: results from an ongoing prospective cohort study, New York City

Molenaar

Rommel

Witte

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: In May-July 2020 in the New York City area, up to 16% of pregnant women had reportedly been infected with SARS-CoV-2. Prior studies found associations between SARS-CoV-2 infection during pregnancy and certain adverse outcomes (e.g., preterm birth, cesarean delivery). These studies relied on reverse transcription polymerase chain reaction (RT-PCR) testing to establish SARS-CoV-2 infection. This led to overrepresentation of symptomatic or acutely ill cases in scientific studies. Objective: To expand our understanding of the effects of SARS-CoV-2 infection during pregnancy on pregnancy outcomes, regardless of symptomatology and stage of infection, by using serological tests to measure IgG antibody levels. Study Design: The Generation C Study is an ongoing prospective cohort study conducted at the Mount Sinai Health System. All pregnant women receiving obstetrical care at the Mount Sinai Hospital and Mount Sinai West Hospital from April 20, 2020 onwards are eligible for participation. For the current analysis, we included participants who had given birth to a liveborn singleton infant on or before August 15, 2020. Blood was drawn as part of routine clinical care; for each woman, we tested the latest sample available to establish seropositivity using a SARS-CoV-2 serologic enzyme-linked immunosorbent assay. Additionally, RT-PCR testing was performed on a nasopharyngeal swab taken during labor and delivery. Pregnancy outcomes of interest (i.e., gestational age at delivery, birth weight, mode of delivery, Apgar score, ICU/NICU admission, and neonatal hospital length of stay) and covariates were extracted from electronic medical records. Among all Generation C participants who had given birth by August 15, 2020 (n=708), we established the SARS-CoV-2 seroprevalence. Excluding women who tested RT-PCR positive at delivery, we conducted crude and adjusted linear and logistic regression models to compare antibody positive women without RT-PCR positivity at delivery with antibody negative women without RT-PCR positivity at delivery. We stratified analyses by race/ethnicity to examine potential effect modification. Results: The SARS-CoV-2 seroprevalence based on IgG measurement was 16.4% (n=116, 95% CI 13.7-19.3). Twelve women (1.7%) were SARS-CoV-2 RT-PCR positive at delivery (11 of these women were seropositive). Seropositive women were generally younger, more often Black or Hispanic, and more often had public insurance and higher pre-pregnancy BMI compared with seronegative women. SARS-CoV-2 seropositivity without RT-PCR positivity at delivery was associated with decreased odds of caesarean delivery (aOR 0.48, 95%CI 0.27; 0.84) compared with seronegative women without RT-PCR positivity at delivery. Stratified by race/ethnicity, the association between seropositivity and decreased odds of caesarean delivery remained for non-Hispanic Black/African-American and Hispanic women, but not for non-Hispanic White women. No other pregnancy outcomes differed by seropositivity, overall or stratified by race/ethnicity. Conclusion: Seropositivity for SARS-CoV-2 without RT-PCR positivity at delivery, suggesting that infection occurred earlier during pregnancy, was not associated with selected adverse maternal or neonatal outcomes among live births in a cohort sample of women from New York City. While non-Hispanic Black and Latina women in our cohort had a higher rate of SARS-CoV-2 seropositivity compared with non-Hispanic White women, we found no increase in adverse maternal or neonatal outcomes among these groups due to infection.

show abstract

“…As for other viruses, passive IgG acquired in utero declines in the newborn blood gradually over a 4-8-month period, whereas breast milk sIgA is likely to be secreted over a long period during the breastfeeding course. SARS-CoV-2specific data would be welcome, and preliminary information on newborn antibody presence has recently emerged [163,226,305]. One such study did not find differences in neonatal outcome after maternal infections with the presence or absence of acquired IgG antibody [305].…”

Section: Controversies With Breast Milkmentioning

confidence: 99%

A Comprehensive Analysis of Maternal and Newborn Disease and Related Control for COVID-19

Cimolai

2021

SN Compr. Clin. Med.

View full text Add to dashboard Cite

The maternal-fetal/newborn unit is established at risk for COVID-19 infection. This narrative review summarizes the contemporary and cumulative publications which detail maternal infection, antenatal and newborn infections, and maternal/fetal/newborn management and prevention. There is a wide spectrum of maternal disease, but the potential for severe disease albeit in a minority is confirmed. COVID-19 carries risk for preterm delivery. Pregnant females can suffer multisystem disease, and co-morbidities play a significant role in risk. Congenital infection has been supported by several anecdotal reports, but strong confirmatory data are few. No typical congenital dysmorphisms are evident. Nevertheless, placental vascular compromise must be considered a risk for the fetus during advanced maternal infections. Clinical manifestations of newborn infection have been mild to moderate and relatively uncommon. Proven antiviral therapy is of yet lacking. The mode of delivery is a medical decision that must include patient risk assessment and patient directives. Both presymptomatic and asymptomatic mothers and offspring can complicate infection control management with the potential for spread to others in several regards. In the interim, infections of the maternal-fetal-newborn unit must be taken seriously both for the disease so caused and the potential for further dissemination of disease.

show abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies at Delivery in Women, Partners, and Newborns

Cited by 50 publications

References 9 publications

Screening of severe acute respiratory syndrome coronavirus-2 infection during labor and delivery using polymerase chain reaction and immunoglobulin testing

Screening of severe acute respiratory syndrome coronavirus-2 infection during labor and delivery using polymerase chain reaction and immunoglobulin testing

Seroprevalence of SARS-CoV-2 during pregnancy and associated outcomes: results from an ongoing prospective cohort study, New York City

A Comprehensive Analysis of Maternal and Newborn Disease and Related Control for COVID-19

Contact Info

Product

Resources

About